Novartis India Ltd Stock Price Today (NSE: NOVARTIND)
Fundamental Score
Novartis India Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Novartis India Ltd share price today is ₹1537.10, down 2.44% on NSE/BSE as of 31 July 2026. Novartis India Ltd (NOVARTIND) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹3.80K (Cr). The 52-week high for NOVARTIND share price is ₹1724.00 and the 52-week low is ₹950.00. At a P/E ratio of 40.76x, NOVARTIND is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 11.63% and a debt-to-equity ratio of 0.00.
Novartis India Ltd Share Price Chart — NSE/BSE Historical Performance
Novartis India Ltd share price chart: 6.42% return over the past month. 52-week high ₹1724.00, 52-week low ₹950.00.
Novartis India Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1575.50 | ₹1607.40 | ₹1519.00 | ₹1537.10 | 27.97K (Cr) | |
| ₹1610.00 | ₹1657.80 | ₹1569.40 | ₹1575.50 | 26.46K (Cr) | |
| ₹1610.00 | ₹1622.80 | ₹1590.40 | ₹1595.90 | 39.67K (Cr) | |
| ₹1654.90 | ₹1654.90 | ₹1573.50 | ₹1579.30 | 24.51K (Cr) | |
| ₹1689.80 | ₹1689.80 | ₹1616.60 | ₹1631.00 | 17.32K (Cr) | |
| ₹1690.00 | ₹1724.00 | ₹1614.40 | ₹1641.20 | 54.37K (Cr) | |
| ₹1676.20 | ₹1713.00 | ₹1628.30 | ₹1701.90 | 51.29K (Cr) | |
| ₹1552.00 | ₹1676.90 | ₹1552.00 | ₹1667.90 | 42.76K (Cr) | |
| ₹1596.00 | ₹1596.50 | ₹1532.60 | ₹1570.10 | 25.14K (Cr) | |
| ₹1539.00 | ₹1667.30 | ₹1539.00 | ₹1596.20 | 1.18L (Cr) |
Novartis India Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1430.00 | ₹1724.00 | ₹1430.00 | ₹1537.10 | +7.49% | |
| ₹1575.00 | ₹1589.20 | ₹1272.10 | ₹1434.40 | -8.93% | |
| ₹1030.00 | ₹1575.00 | ₹1013.00 | ₹1556.60 | +51.13% | |
| ₹991.00 | ₹1059.90 | ₹950.00 | ₹1030.50 | +3.99% |
AI Research Briefing
Powered by Gemini · 2026-04-13
Small-cap turnaround play dependent on PE execution after Novartis AG exit; liquidity a concern.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. Novartis India's board is scheduled to meet on May 12, 2026, to approve the audited financial results for Q4FY26. A trading window closure is in effect from April 1, 2026, until 48 hours after the results are announced.
CORE STORY (THE REAL GAME)
Novartis India is no longer a play on Novartis's global innovation. It's a play on a PE-led operational turnaround of a generics and OTC portfolio after the parent, Novartis AG, sold its 70.68% stake for The market is now waiting for the open offer and subsequent strategic changes.
- PE consortium acquired 70.68% stake
- Mandatory open offer for additional 26% at ₹860.64
- Board meeting to approve FY26 results on May 12
- Successful open offer completion
- Announcement of restructuring plans by PE
- Q4FY26 earnings beat
- Small-cap: liquidity risk
- Dependence on PE turnaround
- Name change: loss of Novartis brand
ChrysCapital-led consortium acquired 70.68% stake; open offer suggests further accumulation.
Indian pharma sector transitioning to value-led innovation in biologics and biosimilars.
Free Cash Flow 5Y: ₹202.03 Cr - Yes.
3-6 month thesis: Monitor open offer success and PE's restructuring plan. Watch for Q4FY26 results and initial signs of operational improvements.
Primary Thesis Risk
PE turnaround fails to materialize, leading to de-rating.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Novartis India Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Novartis India Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of NOVARTIND across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Excellent ROCE Performance (16.25%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (18.81%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Excellent EPS Growth (34.88% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (34.88% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (103.90x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹317.74 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (70.68%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 40.76x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-13.82%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Growth History (-1.46% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Limited Institutional Interest (FII+DII: 0.70%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Novartis India Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Novartis India Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Novartis India LtdNovartis India ...Selected✓ NOVARTIND • 500672 | 53.2/100 | ₹1537.10₹1537 | ₹3797.75₹3797.75 | 40.76Average 40.8 Average | 11.63%Average 11.63% Average | 16.25%Good 16.25% Good | 0.00Excellent 0.0 Excellent | 34.88%Excellent 34.88% Excellent | -1.46%Poor -1.46% Poor | 1.62% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Novartis India Ltd PE Ratio History
Historical price-to-earnings ratio for NOVARTIND — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2023 | ₹41.86 | ₹672.25 | 16.1x |
| FY 2021 | ₹8.46 | ₹776.20 | 91.7x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Novartis India Ltd Dividend History
Annual cash dividends paid by NOVARTIND — dividend yield 1.62%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹61.73 Cr |
| FY 2024 | ₹117.28 Cr |
| FY 2023 | ₹24.69 Cr |
| FY 2022 | ₹24.69 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Novartis India Ltd Quarterly Performance
Latest quarterly metrics for NOVARTIND — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
7.95%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-13.82%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-1.46%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
34.88%
Compounded annual net profit growth over 5 years
Novartis India Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for NOVARTIND — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Novartis India Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Novartis India Ltd (NOVARTIND) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Novartis India Ltd
About NOVARTIND (Novartis India Ltd)
Novartis India Ltd is a prominent player in the Indian pharmaceutical landscape, dedicated to advancing healthcare solutions across a spectrum of therapeutic areas. With a strong c...ommitment to innovation and patient well-being, the company develops, manufactures, and markets a diverse portfolio of pharmaceutical products. These offerings address critical medical needs, contributing to improved health outcomes and enhanced quality of life for patients throughout India. Novartis India's unwavering focus on research and development ensures a continuous pipeline of innovative therapies, solidifying its position as a leader in the Indian pharmaceutical industry. The company's product range encompasses vital medications in diverse areas, most notably in bone and pain management with the well-established Voveran brand. Further extending its reach, Novartis India provides essential therapies in transplantation immunology, offering hope and improved outcomes for patients undergoing organ transplantation through brands like Simulect, Certican, Sandimmun, Neoral, and Myfortic. In the field of neuroscience, Novartis India contributes significantly by providing treatments for neurological disorders, with established brands such as Tegrital and Exelon, improving the lives of patients facing neurological challenges. Headquartered in the bustling city of Mumbai, India, Novartis India has a rich heritage dating back to its incorporation in 1947. As a subsidiary of the globally renowned Novartis AG, it leverages the parent company's extensive resources, cutting-edge research, and global network to deliver high-quality pharmaceutical products and services to the Indian market. Novartis India's presence is a testament to its enduring commitment to addressing the evolving healthcare needs of the nation, contributing to the overall health and well-being of the Indian population.
Company Details
Key Leadership
NOVARTIND Share Price: Frequently Asked Questions
What is the current share price of Novartis India Ltd?
Novartis India Ltd (NOVARTIND) trades at ₹1537.10 on NSE and BSE. Market cap ₹3.80K (Cr). Educational data only.
What is the P/E ratio of Novartis India Ltd?
Novartis India Ltd has a P/E of 40.76x vs industry average 34.89x.
What is the Bull Run score for Novartis India Ltd?
Novartis India Ltd has a Bull Run score of 53.2/100 based on 25+ financial parameters.
Does Novartis India Ltd pay dividends?
Novartis India Ltd has a dividend yield of 1.62%. Past dividends don't guarantee future payments.
What is the ROE of Novartis India Ltd?
Novartis India Ltd has ROE of 11.63%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Novartis India Ltd?
Novartis India Ltd has debt-to-equity of 0.00.
Is Novartis India Ltd a good investment?
Bull Run gives Novartis India Ltd a score of 53.2/100. This is not investment advice — consult a SEBI-registered advisor.